Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-37878973

ABSTRACT

Isoniazid is a key component of tuberculosis treatment. Adequate exposure is a determinant for therapeutic success; however, considerable inter- and intraindividual variations in drug plasma levels can lead to unfavorable outcomes. While some predictors of isoniazid levels are well-known, others, such as sex, yield controversial results, requiring further investigation to optimize exposure. This study investigates whether the sex of patients influences the dose administered and the concentrations of isoniazid in plasma. Levels of isoniazid were associated with the N-acetyltransferase 2 phenotypes. A total of 76 male and 58 female patients were included. Isoniazid was measured by high-performance liquid chromatography, and N-acetyltransferase 2 phenotypes were assessed using molecular techniques. The results show that the dose administered, expressed in mg/kg, was higher in females, but the plasma levels were similar between both sexes. Among patients, 46.2%, 38.8%, and 15% were slow, intermediate, and fast acetylators, respectively. As expected, isoniazid levels were associated with the acetylation phenotypes, with higher concentrations in the slow acetylators. Thus, sex-related difference in isoniazid levels is due to the body weight of patients, and the optimized dose regimen based on patient weight and acetylator phenotypes can improve the treatment outcomes.


Subject(s)
Isoniazid , Tuberculosis, Pulmonary , Humans , Male , Female , Antitubercular Agents/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Phenotype , Acetyltransferases/genetics , Acetyltransferases/therapeutic use
2.
Article in English | LILACS-Express | LILACS | ID: biblio-1521579

ABSTRACT

ABSTRACT Isoniazid is a key component of tuberculosis treatment. Adequate exposure is a determinant for therapeutic success; however, considerable inter- and intraindividual variations in drug plasma levels can lead to unfavorable outcomes. While some predictors of isoniazid levels are well-known, others, such as sex, yield controversial results, requiring further investigation to optimize exposure. This study investigates whether the sex of patients influences the dose administered and the concentrations of isoniazid in plasma. Levels of isoniazid were associated with the N-acetyltransferase 2 phenotypes. A total of 76 male and 58 female patients were included. Isoniazid was measured by high-performance liquid chromatography, and N-acetyltransferase 2 phenotypes were assessed using molecular techniques. The results show that the dose administered, expressed in mg/kg, was higher in females, but the plasma levels were similar between both sexes. Among patients, 46.2%, 38.8%, and 15% were slow, intermediate, and fast acetylators, respectively. As expected, isoniazid levels were associated with the acetylation phenotypes, with higher concentrations in the slow acetylators. Thus, sex-related difference in isoniazid levels is due to the body weight of patients, and the optimized dose regimen based on patient weight and acetylator phenotypes can improve the treatment outcomes.

4.
Article in English | MEDLINE | ID: mdl-31844010

ABSTRACT

Mefloquine shows a high capacity to bind plasma proteins, which influences the amount of drug in erythrocytes. The study investigated the association of lipids levels with plasma concentrations of mefloquine and carboxy-mefloquine in 85 Brazilian patients with uncomplicated falciparum malaria. There were no significant associations between the total cholesterol or triglycerides with plasma concentrations of mefloquine and of carboxy-mefloquine. Lipoprotein levels explained 25.68% and 18.31% of mefloquine and carboxy-mefloquine plasma concentrations, respectively.


Subject(s)
Antimalarials/blood , Artesunate/blood , Malaria, Falciparum/drug therapy , Mefloquine/analogs & derivatives , Mefloquine/blood , Plasmodium falciparum/drug effects , Adult , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Artesunate/pharmacokinetics , Artesunate/pharmacology , Biotransformation , Brazil , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cholesterol, VLDL/blood , Drug Therapy, Combination , Erythrocytes/drug effects , Erythrocytes/metabolism , Erythrocytes/parasitology , Humans , Malaria, Falciparum/blood , Malaria, Falciparum/parasitology , Male , Mefloquine/pharmacokinetics , Mefloquine/pharmacology , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , Severity of Illness Index , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...